{
  "report_rows": [
    {
      "kpi": "Core EPS (adj., diluted)",
      "prediction": "MISS",
      "answer": "pred ~$3.05 vs. cons ~$3.19",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "P&C headline combined ratio (Business + Personal blended)",
      "prediction": "MISS",
      "answer": "pred ~93.0 vs. cons ~90.8 (higher ratio = worse profitability)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Net investment income (pre-tax)",
      "prediction": "BEAT",
      "answer": "pred ~$770M vs. cons ~$745M",
      "confidence": "HIGH"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 P&C catastrophe load / current-accident-year cat assumption",
      "prediction": "UNCHANGED",
      "answer": "guide ~5.5% of NPE unchanged vs. cons ~5.5% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Q3 2026 share repurchase pace",
      "prediction": "UNCHANGED",
      "answer": "guide ~$450M/quarter vs. cons ~$450M (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Business Insurance expense ratio glide path (sub-30% target)",
      "prediction": "UNCHANGED",
      "answer": "guide ~29.5%-29.8% exit vs. cons ~29.8% (FY2026 exit)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Employee Benefits core earnings margin",
      "prediction": "LOWER",
      "answer": "guide ~7.0%-7.5% vs. cons ~8.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Full-year 2026 net investment income growth",
      "prediction": "BETTER",
      "answer": "guide ~+8%-10% y/y vs. cons ~+6% y/y (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A cat-driven EPS miss against a stock that has already rallied ~10% off its June lows into the print (like TRV's post-beat sell-the-news reaction on valuation/downgrades) sets up limited room for a relief rally even if underlying combined ratios and NII are solid. Out-period math works against the stock: analysts will likely trim FY26 EPS to reflect the incremental cat charge (which flows through the full-year cat budget even if within the aggregate-treaty attachment), while lingering overhangs (legacy abuse reserve trend, soft group-disability/PFML margins, decelerating ex-comp BI pricing) give sell-side more reason to shade estimates down rather than back-fill the miss with a 'one-time cat' narrative, producing continued mild downward drift over the week rather than an immediate rebound.",
  "day5_confidence": "LOW"
}